Latest News
Conference Coverage
REGOBONE: Regorafenib shows efficacy in metastatic osteosarcoma
Regorafenib appears to be active in patients with metastatic osteosarcomas, based on results from REGOBONE a non-comparative phase 2, double-blind...
Conference Coverage
PVd improved survival in lenalidomide-exposed myeloma
CHICAGO – The OPTIMISMM study examined patients who had received at least two prior cycles of lenalidomide.
Conference Coverage
Voxelotor cut transfusions in compassionate use sickle cell cohort
WASHINGTON – Hospitalizations and transfusions were down by about two-thirds in this severely affected group.
Feature
Geriatric assessments could fine-tune cancer care for older adults
The goal is to better identify which patients can tolerate intensive chemotherapy and which patients may need modified treatment regimens.
Conference Coverage
Sorafenib boosts PFS in desmoid tumor patients
Sorafenib was well tolerated with significantly improved progression-free survival in select patients with desmoid tumors, reported Mrinal M....
Conference Coverage
SARCO24: Regorafenib falls short for treatment-refractory liposarcoma
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, of Duke...
News
Cost led to missed care for 4.5% of Americans in 2017
Steady decline in national rate appears to have halted.
News
FDA approves encorafenib/binimetinib for advanced melanoma with BRAF mutations
The FDA also approved a companion diagnostic to help identify candidates for the combination therapy.
Conference Coverage
EPAZ: Pazopanib matches doxorubicin without the neutropenia in elderly patients
Pazopanib can be considered as a first line alternative treatment to doxorubicin in patients over age 60 with advanced, inoperable soft tissue...
Latest News
ENLIVEN: Pexidartinib improves symptoms, function in patients with advanced tenosynovial giant cell tumors
Pexidartinib significantly improved overall response rates and functioning in patients with advanced tenosynovial giant cell tumors (TGCT), based...
Conference Coverage
CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort
CHICAGO – Could liso-cel be the next CAR T-cell therapy to compete in DLBCL?